Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation - 2Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 35 Bike Brands for Ordinary Use
- 4Doggie diversity in size and shape began at least 11,000 years ago
- 5Zelensky names spy chief to head presidential office after corruption row
- Hamas urges Hezbollah to kidnap Israeli soldiers in wake of Knesset passing death penalty bill
- Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- 21 Things You Ought to Never Tell Your Childless Companion
- Moving Wedding Objections for Paramount Functions
- The Development of Shipping: Controlling Towards a More Associated Future
- Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- Abbott issues US device correction for some glucose monitors over faulty readings risk
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
